These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 20415898)

  • 1. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
    Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
    Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
    Vincenti F; Charpentier B; Vanrenterghem Y; Rostaing L; Bresnahan B; Darji P; Massari P; Mondragon-Ramirez GA; Agarwal M; Di Russo G; Lin CS; Garg P; Larsen CP
    Am J Transplant; 2010 Mar; 10(3):535-46. PubMed ID: 20415897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
    Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
    Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
    Larsen CP; Grinyó J; Medina-Pestana J; Vanrenterghem Y; Vincenti F; Breshahan B; Campistol JM; Florman S; Rial Mdel C; Kamar N; Block A; Di Russo G; Lin CS; Garg P; Charpentier B
    Transplantation; 2010 Dec; 90(12):1528-35. PubMed ID: 21076381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.
    Durrbach A; Pestana JM; Florman S; Del Carmen Rial M; Rostaing L; Kuypers D; Matas A; Wekerle T; Polinsky M; Meier-Kriesche HU; Munier S; Grinyó JM
    Am J Transplant; 2016 Nov; 16(11):3192-3201. PubMed ID: 27130868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
    Rostaing L; Neumayer HH; Reyes-Acevedo R; Bresnahan B; Florman S; Vitko S; Heifets M; Xing J; Thomas D; Vincenti F
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2696-704. PubMed ID: 21921152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
    Charpentier B; Medina Pestana JO; Del C Rial M; Rostaing L; Grinyó J; Vanrenterghem Y; Matas A; Zhang R; Mühlbacher F; Pupim L; Florman S
    Am J Transplant; 2013 Nov; 13(11):2884-91. PubMed ID: 24103072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
    Vanrenterghem Y; Bresnahan B; Campistol J; Durrbach A; Grinyó J; Neumayer HH; Lang P; Larsen CP; Mancilla-Urrea E; Pestana JM; Block A; Duan T; Glicklich A; Gujrathi S; Vincenti F
    Transplantation; 2011 May; 91(9):976-83. PubMed ID: 21372756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
    Rostaing L; Vincenti F; Grinyó J; Rice KM; Bresnahan B; Steinberg S; Gang S; Gaite LE; Moal MC; Mondragón-Ramirez GA; Kothari J; Pupim L; Larsen CP
    Am J Transplant; 2013 Nov; 13(11):2875-83. PubMed ID: 24047110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
    Vincenti F; Larsen CP; Alberu J; Bresnahan B; Garcia VD; Kothari J; Lang P; Urrea EM; Massari P; Mondragon-Ramirez G; Reyes-Acevedo R; Rice K; Rostaing L; Steinberg S; Xing J; Agarwal M; Harler MB; Charpentier B
    Am J Transplant; 2012 Jan; 12(1):210-7. PubMed ID: 21992533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
    Florman S; Vincenti F; Durrbach A; Abouljoud M; Bresnahan B; Garcia VD; Mulloy L; Rice K; Rostaing L; Zayas C; Calderon K; Meier-Kriesche U; Polinsky M; Yang L; Medina Pestana J; Larsen CP
    Clin Transplant; 2018 Apr; 32(4):e13225. PubMed ID: 29461660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated safety profile analysis of belatacept in kidney transplant recipients.
    Grinyó J; Charpentier B; Pestana JM; Vanrenterghem Y; Vincenti F; Reyes-Acevedo R; Apanovitch AM; Gujrathi S; Agarwal M; Thomas D; Larsen CP
    Transplantation; 2010 Dec; 90(12):1521-7. PubMed ID: 21088650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
    Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
    J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.
    Florman S; Becker T; Bresnahan B; Chevaile-Ramos A; Carvalho D; Grannas G; Muehlbacher F; O'Connell PJ; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2017 Jan; 17(1):180-190. PubMed ID: 27232116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2010 Dec; 15(6):697-702. PubMed ID: 20930638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.